{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:13:01Z","timestamp":1772554381816,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873919"],"award-info":[{"award-number":["81873919"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00270-022-03141-y","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T19:08:21Z","timestamp":1649704101000},"page":"780-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)\u2013Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Tao","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"issue":"3","key":"3141_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3141_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00000658-200203000-00009","volume":"235","author":"RT Poon","year":"2002","unstructured":"Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373\u201382.","journal-title":"Ann Surg"},{"issue":"5","key":"3141_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","volume":"63","author":"J Bruix","year":"2014","unstructured":"Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844\u201355.","journal-title":"Gut"},{"issue":"5","key":"3141_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u201371.","journal-title":"Hepatology"},{"issue":"2","key":"3141_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1148\/radiol.10101058","volume":"258","author":"GE Chung","year":"2011","unstructured":"Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258(2):627\u201334.","journal-title":"Radiology"},{"issue":"4","key":"3141_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","volume":"31","author":"ZW Peng","year":"2013","unstructured":"Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426\u201332.","journal-title":"J Clin Oncol"},{"key":"3141_CR7","first-page":"1341863","volume":"2020","author":"Y Liu","year":"2020","unstructured":"Liu Y, Li Y, Gao F, Zhang Q, Yang X, Zhu B, Niu S, Huang Y, Hu Y, Li W, et al. Comparison of transcatheter arterial chemoembolization-radiofrequency ablation and transcatheter arterial chemoembolization alone for advanced hepatocellular carcinoma with macrovascular invasion using propensity score analysis: a retrospective cohort study. J Oncol. 2020;2020:1341863.","journal-title":"J Oncol"},{"issue":"46","key":"3141_CR8","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.M704041200","volume":"282","author":"M Charbonneau","year":"2007","unstructured":"Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme\/ADAM17 expression by synovial cells. J Biol Chem. 2007;282(46):33714\u201324.","journal-title":"J Biol Chem"},{"issue":"1","key":"3141_CR9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1080\/10717544.2020.1831102","volume":"27","author":"P Ma","year":"2020","unstructured":"Ma P, Chen J, Qu H, Li Y, Li X, Tang X, Song Z, Xin H, Zhang J, Nai J, et al. Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere. Drug Deliv. 2020;27(1):1412\u201324.","journal-title":"Drug Deliv"},{"issue":"5","key":"3141_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10147-003-0328-6","volume":"8","author":"Y Takada","year":"2003","unstructured":"Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol. 2003;8(5):332\u20135.","journal-title":"Int J Clin Oncol"},{"key":"3141_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2018.02.024","volume":"421","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Wu J, Liu X, Liang M, Zhou X, Ouyang S, Yao J, Wang J, Luo B. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018;421:73\u201381.","journal-title":"Cancer Lett"},{"key":"3141_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1479-5876-10-230","volume":"10","author":"J Kong","year":"2012","unstructured":"Kong J, Kong L, Kong J, Ke S, Gao J, Ding X, Zheng L, Sun H, Sun W. After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma. J Transl Med. 2012;10:230.","journal-title":"J Transl Med"},{"issue":"1","key":"3141_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3141_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41401-018-0058-y","volume":"40","author":"K Zhou","year":"2019","unstructured":"Zhou K, Zhang JW, Wang QZ, Liu WY, Liu JL, Yao L, Cai MM, Ni SY, Cai QY, Wang GJ, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. Acta Pharmacol Sin. 2019;40(4):556\u201362.","journal-title":"Acta Pharmacol Sin"},{"issue":"26","key":"3141_CR15","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219\u201325.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3141_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21037\/atm-20-5298","volume":"8","author":"W He","year":"2020","unstructured":"He W, Liao L, Hu D, Li B, Wang C, Qiu J, Liao Y, Liu W, Yang Z, Zhang Y, et al. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study. Ann Transl Med. 2020;8(16):1000.","journal-title":"Ann Transl Med"},{"issue":"15_Suppl","key":"3141_CR17","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2020.38.15_suppl.4507","volume":"38","author":"Q Li","year":"2020","unstructured":"Li Q, Qin S, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study. J Clin Oncol. 2020;38(15_Suppl):4507\u20134507.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3141_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","volume":"18","author":"W Lu","year":"2017","unstructured":"Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther. 2017;18(6):433\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3141_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1148\/radiol.2018171541","volume":"287","author":"Z Peng","year":"2018","unstructured":"Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287(2):705\u201314.","journal-title":"Radiology"},{"issue":"1","key":"3141_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1148\/radiol.2018172028","volume":"288","author":"K Zhu","year":"2018","unstructured":"Zhu K, Huang J, Lai L, Huang W, Cai M, Zhou J, Guo Y, Chen J. Medium or large hepatocellular carcinoma: sorafenib combined with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;288(1):300\u20137.","journal-title":"Radiology"},{"key":"3141_CR21","unstructured":"Institute NC. Common terminology criteria for adverse events, version 4.03. NIH Publication 2010; 09(5410)."},{"issue":"1","key":"3141_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"key":"3141_CR23","first-page":"6298502","volume":"2019","author":"F Liu","year":"2019","unstructured":"Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial chemoembolization combined with radiofrequency ablation in the treatment of stage B1 intermediate hepatocellular carcinoma. J Oncol. 2019;2019:6298502.","journal-title":"J Oncol"},{"issue":"7","key":"3141_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jvir.2007.04.022","volume":"18","author":"H Takaki","year":"2007","unstructured":"Takaki H, Yamakado K, Nakatsuka A, Fuke H, Murata K, Shiraki K, Takeda K. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. J Vasc Interv Radiol JVIR. 2007;18(7):856\u201361.","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"6","key":"3141_CR25","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1245\/s10434-011-1673-8","volume":"18","author":"JH Kim","year":"2011","unstructured":"Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, Kim PN. Medium-sized (31\u201350 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18(6):1624\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3141_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00330-012-2561-8","volume":"23","author":"HY Lee","year":"2013","unstructured":"Lee HY, Rhim H, Lee MW, Kim YS, Choi D, Park MJ, Kim YK, Kim SH, Lim HK. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013;23(1):190\u20137.","journal-title":"Eur Radiol"},{"issue":"5","key":"3141_CR27","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/hep.26526","volume":"58","author":"S Yoshida","year":"2013","unstructured":"Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson SC, Schuppan D. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58(5):1667\u201380.","journal-title":"Hepatology"},{"issue":"10","key":"3141_CR28","first-page":"2375","volume":"6","author":"Z Li","year":"2016","unstructured":"Li Z, Xue TQ, Chen XY. Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE. Am J Cancer Res. 2016;6(10):2375\u201385.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"3141_CR29","first-page":"773","volume":"32","author":"A Sasaki","year":"2006","unstructured":"Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2006;32(7):773\u20139.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"11","key":"3141_CR30","first-page":"3394","volume":"22","author":"H Xu","year":"2018","unstructured":"Xu H, Ren YJ, Liu K, Min XL, Yang L, Zhou Y, Zheng J, Yang C. Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions. Eur Rev Med Pharmacol Sci. 2018;22(11):3394\u2013401.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"3141_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090\u20138.","journal-title":"J Hepatol"},{"issue":"4","key":"3141_CR32","first-page":"791","volume":"9","author":"H Yuan","year":"2019","unstructured":"Yuan H, Lan Y, Li X, Tang J, Liu F. Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone. Am J Cancer Res. 2019;9(4):791\u20139.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"3141_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.canlet.2016.01.015","volume":"373","author":"S Peng","year":"2016","unstructured":"Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T, Tsung A, Tohme S, Huang H, Zhang Q, et al. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by apatinib. Cancer Lett. 2016;373(2):193\u2013202.","journal-title":"Cancer Lett"},{"key":"3141_CR34","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fonc.2020.00970","volume":"10","author":"X Kan","year":"2020","unstructured":"Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol. 2020;10:970.","journal-title":"Front Oncol"},{"issue":"20","key":"3141_CR35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"key":"3141_CR36","doi-asserted-by":"publisher","first-page":"621639","DOI":"10.3389\/fonc.2021.621639","volume":"11","author":"T Ouyang","year":"2021","unstructured":"Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review. Front Oncol. 2021;11:621639.","journal-title":"Front Oncol"},{"key":"3141_CR37","doi-asserted-by":"publisher","first-page":"578633","DOI":"10.3389\/fonc.2020.578633","volume":"10","author":"X Ding","year":"2020","unstructured":"Ding X, Sun W, Chen J, Li W, Shen Y, Guo X, Teng Y, Liu X, Sun S, Wei J, et al. Percutaneous radiofrequency ablation combined with transarterial chemoembolization plus sorafenib for large hepatocellular carcinoma invading the portal venous system: a prospective randomized study. Front Oncol. 2020;10:578633.","journal-title":"Front Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03141-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T20:12:14Z","timestamp":1652904734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3141"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03141-y","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"9 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest in this manuscript, and the manuscript has been approved for publication by all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}